Search

Your search keyword '"Ravi Uppaluri"' showing total 4 results
Start Over Author "Ravi Uppaluri" Publisher american society of clinical oncology (asco)
4 results on '"Ravi Uppaluri"'

1. A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN)

Author

Glenn J. Hanna, Laura Ma, Patricia McHugh, Julian Huang, Jochen H. Lorch, Alec Kacew, Danielle N. Margalit, Ravi Uppaluri, Nicole G. Chau, Laura A. Goguen, Ethan James Harris, Roy B. Tishler, Anne O'Neill, Guilherme Rabinowits, Robert I. Haddad, Donald J. Annino, and Jonathan D. Schoenfeld

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Squamous cell cancer, business.industry, Locally advanced, Phase i study, Concurrent chemoradiotherapy, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In patient, business, Head and neck, 030217 neurology & neurosurgery, PI3K/AKT/mTOR pathway
Abstract

6071Background: Prognosis in smokers with LASCCHN remains poor. Activating mutations of PI3K are linked to poor outcome and PI3K activation in response to RT is implicated in resistance to CRT. Met...

Published
2018

2. The role of cetuximab in induction chemotherapy: Comparison of APF-C (nab-paclitaxel, cisplatin, 5-FU + cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)

Author

Douglas Adkins, Jessica C. Ley, Tanya Marya Wildes, Loren S. Michel, Jason Rich, Randal Paniello, Ravi Uppaluri, Wade L. Thorstad, Hiram Alberto Gay, Kathryn Trinkaus, Toni Rachocki, and Brian Nussenbaum

Subjects
Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, Cetuximab, business.industry, Locally advanced, Induction chemotherapy, medicine.disease, Head and neck squamous-cell carcinoma, digestive system diseases, stomatognathic diseases, Internal medicine, otorhinolaryngologic diseases, medicine, Overall survival, In patient, business, neoplasms, medicine.drug, Nab-paclitaxel
Abstract

6042 Background: Cetuximab (C) improved overall survival (OS) in patients (pts) with HNSCC when added to definitive RT or to palliative chemotherapy; however, the role of cetuximab in induction che...

Published
2015

3. Prospective study of a tailored comprehensive cancer gene (TCCG) set built on a next generation sequencing (NGS) platform in incurable head and neck squamous cell carcinoma (The Pro-TCCG Protocol)

Author

Jessica Ley, Andrew J. Bredemeyer, Tanya M. Wildes, Douglas Adkins, Loren S. Michel, Ling Chen, Kevin Chen, and Ravi Uppaluri

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Head and neck squamous-cell carcinoma, DNA sequencing, Targeted therapy, Internal medicine, medicine, Cancer gene, Prospective cohort study, business, EGFR inhibitors
Abstract

e17076 Background: The genetic landscape of HNSCC is heterogeneous. However, only one targeted therapy (an EGFR inhibitor) has shown efficacy, albeit modest. We hypothesized that a TCCG set of 40 c...

Published
2015

4. Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Author

Jessica C. Ley, Brian Nussenbaum, Jason Diaz, Jason Rich, Randal Paniello, Ravi Uppaluri, Wade L. Thorstad, Hiram Alberto Gay, Toni Rachocki, Jaisy Varges, Tanya Marya Wildes, Loren S. Michel, and Douglas Adkins

Subjects
Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Cetuximab, business.industry, Locally advanced, Induction chemotherapy, medicine.disease, Primary tumor, Internal medicine, medicine, In patient, Head and neck, business, medicine.drug, Nab-paclitaxel
Abstract

6013 Background: Achievement of a favorable (> PR) response (particularly CR) at the PTS to IC predicts a higher likelihood of long-term disease control after definitive chemoradiotherapy (CRT) in ...

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results